Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $830.81M |
| Gross Profit (TTM) | $816.73M |
| EBITDA | $8.08M |
| Operating Margin | 16.10% |
| Return on Equity | 8.23% |
| Return on Assets | 0.47% |
| Revenue/Share (TTM) | $7.97 |
| Book Value | $6.54 |
| Price-to-Book | 18.00 |
| Price-to-Sales (TTM) | 14.33 |
| EV/Revenue | 14.93 |
| EV/EBITDA | 1405.48 |
| Quarterly Earnings Growth (YoY) | 24.10% |
| Quarterly Revenue Growth (YoY) | 31.70% |
| Shares Outstanding | $108.10M |
| Float | $96.48M |
| % Insiders | 11.46% |
| % Institutions | 76.92% |
Volatility is currently expanding
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CORT and any ticker you trade — then tracks every position and per-strategy win rate.
